中华结核和呼吸杂志Pub Date : 2026-06-12DOI: 10.3760/cma.j.cn112147-20251104-00674
{"title":"[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112147-20251104-00674","DOIUrl":"10.3760/cma.j.cn112147-20251104-00674","url":null,"abstract":"<p><p>Multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB) pose significant challenges to global tuberculosis prevention and treatment efforts. At present, the chemotherapy of MDR/RR-TB is still hampered by prolonged treatment duration and suboptimal success rates. In 2019, the Chinese Medical Association Tuberculosis Branch issued the Chinese Expert Consensus on the Treatment of MDR-TB and RR-TB, which has provided essential guidance for standardizing the diagnosis, treatment, and clinical management of MDR/RR-TB in China. In response to recent advances in global evidence-based medicine and in consideration of China's specific context, the Chinese Medical Association Tuberculosis Branch recently convened a panel of experts to develop the <i>Chinese Guidelines for the Chemotherapy of MDR/RR-TB (2026 Edition)</i>. This guideline provides updated recommendations regarding the definition of drug-resistant tuberculosis, selection and adjustment of short-course and long-course regimens, treatment monitoring, management of special populations, and standardized management of adverse drug reactions. Each recommendation is supported by an evidence-based rationale, the clinical questions addressed, and practical implementation suggestions. A total of 14 recommendations are presented, aiming to provide a robust clinical evidence base and to support informed decision-making for the standardized treatment of MDR/RR-TB. The key recommendations are as follows.<b>Recommendation 1:</b> For adolescents (aged 14 years and above) and adults with MDR/RR-TB, the 6-month regimen comprising bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is recommended over the 9-month or longer (18-month) regimens (1, B).<b>Recommendation 2:</b> For MDR/RR-TB patients with or without fluoroquinolones resistance (including children of all ages, pregnant and breastfeeding women), the 6-month regimen comprising bedaquiline, delamanid, linezolid, levofloxacin, and clofazimine (BDLLfxC) is recommended (1, B).<b>Recommendation 3:</b> For MDR/RR-TB patients susceptible to fluoroquinolones, the 9-month all-oral regimen comprising bedaquiline, levofloxacin (or moxifloxacin), protionamide (or linezolid for two months), clofazimine, ethambutol, high-dose isoniazid, and pyrazinamide [4-6 Bdq (6m)-Lfx (Mfx)-Pto (Lzd2m)-Cfz-E-H<sup>high-dose</sup>-Z/5Lfx (Mfx)-Cfz-E-Z] is recommended over longer (18-month) regimens (2, B).<b>Recommendation 4:</b> For MDR/RR-TB patients susceptible to fluoroquinolones, the modified 9-month all-oral regimens (BLMZ, BLLfxCZ and BDLLfxZ) are recommended over the currently recommended longer (18 months) regimens. The recommended order of priority among these regimens is BLMZ>BLLfxCZ>BDLLfxZ(2, B).<b>Recommendation 5:</b> When drug accessibility is limited, for MDR/RR-TB patients susceptible to both fluoroquinolones and amikacin, the 9- to 12-month short-course regimen containing an injectable agent may be used in place of t","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 6","pages":"623-643"},"PeriodicalIF":0.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-06-12DOI: 10.3760/cma.j.cn112147-20251024-00660
C X Liu, J N Gong, Y H Yang
{"title":"[Pathogenesis of fibrosing mediastinitis caused by common etiologies].","authors":"C X Liu, J N Gong, Y H Yang","doi":"10.3760/cma.j.cn112147-20251024-00660","DOIUrl":"10.3760/cma.j.cn112147-20251024-00660","url":null,"abstract":"<p><p>Fibrosing mediastinitis (FM) is a rare disease characterized primarily by symptoms caused by compression of mediastinal structures. Currently, the diagnosis and treatment of FM focus predominantly on addressing mechanical complications, while understanding of its etiology and pathogenesis remains limited. The etiology of FM is complex and diverse, and it remains unclear whether different causative factors share common pathogenic mechanisms. This article systematically reviews existing literature to elucidate the underlying pathogenic mechanisms of FM caused by common etiologies from the perspective of primary diseases or comorbidities, with particular emphasis on the roles of inflammatory activation, immune responses, and fibrotic processes in its onset and progression. Studies indicate that FM driven by different etiologies exhibit variations in initiation and perpetuation mechanisms, suggesting the need for further mechanistic research targeting specific causative factors to advance precision diagnosis and treatment of this disease.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 6","pages":"699-704"},"PeriodicalIF":0.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-06-12DOI: 10.3760/cma.j.cn112147-20250729-00450
W S Xu, Y H Wan, J Q Zhao, X D Mu
{"title":"[STAT3 gene-related hyper-IgE syndrome complicated by pulmonary aspergillosis: a case report].","authors":"W S Xu, Y H Wan, J Q Zhao, X D Mu","doi":"10.3760/cma.j.cn112147-20250729-00450","DOIUrl":"10.3760/cma.j.cn112147-20250729-00450","url":null,"abstract":"<p><p>Patients with signal transducer and activator of transcription 3-related hyper-IgE syndrome (STAT3-HIES) complicated by invasive pulmonary aspergillosis typically show rapid disease progression, a tendency toward systemic dissemination, prolonged treatment courses, frequent relapse after therapy, and a poor prognosis. Some patients with STAT3-HIES also develop allergic bronchopulmonary aspergillosis (ABPA). Conventional treatment of ABPA relies primarily on glucocorticoids; however, because patients with STAT3-HIES already have immune deficiency, glucocorticoid therapy may further suppress immune function. New therapeutic strategies using biologic agents for STAT3-HIES complicated by ABPA are urgently needed. We report a patient with STAT3-HIES complicated by invasive pulmonary aspergillosis and ABPA who was treated with oral posaconazole, bronchoscopic instillation of amphotericin B, and omalizumab. Afte treatment, the patient's cough was alleviated, pulmonary function improved, mucus plugs resolved, and serum total IgE decreased significantly. By summarizing this case together with a literature review, we hope to raise awareness of STAT3-HIES complicated by invasive pulmonary aspergillosis and ABPA and to improve future treatment strategies.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 6","pages":"673-677"},"PeriodicalIF":0.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20250902-00537
Y K Jiang, L P Zhu
{"title":"[Immune reconstitution inflammatory syndrome associated with invasive pulmonary fungal disease].","authors":"Y K Jiang, L P Zhu","doi":"10.3760/cma.j.cn112147-20250902-00537","DOIUrl":"10.3760/cma.j.cn112147-20250902-00537","url":null,"abstract":"<p><p>Immune reconstitution inflammatory syndrome (IRIS) refers to an exaggerated inflammatory response to existing infections or latent pathogens that occurs during rapid immune recovery in immunocompromised hosts, paradoxically leading to clinical deterioration despite appropriate treatment. IRIS is commonly observed in patients with human immunodeficiency virus (HIV)-associated tuberculosis and cryptococcal meningitis after starting antiretroviral therapy. However, it can also occur in immunocompromised individuals without HIV, which remains relatively under-recognized, particularly following neutrophil recovery after chemotherapy for acute leukemia or hematopoietic stem cell transplantation, during the post-operative phase of anti-rejection therapy following solid organ transplantation, or after the rapid reduction or withdrawal of corticosteroids or immunosuppressants, <i>etc</i>. This article summarizes the definition, clinical characteristics, diagnosis, treatment, and prevention of IRIS associated with invasive pulmonary fungal diseases. Clinical management requires accurate identification and careful evaluation to guide optimal and prompt intervention. Appropriate timing of antifungal treatment, initiation of antiretroviral therapy, and adjustment of immunosuppressive agents are crucial to reduce the risk of IRIS and prevent related morbidity and mortality.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"500-502"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20251202-00760
F L Liu, J Zhang, J Y Li
{"title":"[Interstitial pneumonia with primary pulmonary atypical carcinoid tumor and multiple brain metastases: a case report].","authors":"F L Liu, J Zhang, J Y Li","doi":"10.3760/cma.j.cn112147-20251202-00760","DOIUrl":"10.3760/cma.j.cn112147-20251202-00760","url":null,"abstract":"<p><p>Pulmonary carcinoid (PC) is a relatively rare neuroendocrine tumor, accounting for approximately 1%-2% of all lung tumors. According to histopathological characteristics, it can be categorized into low-grade typical carcinoid (TC) and intermediate-grade atypical carcinoid (AC), with AC being less common, representing about 10% of all pulmonary carcinoids. The clinical symptoms and imaging manifestations of AC lack specificity, with solitary pulmonary nodules as the major radiological feature. Cases of interstitial lung disease (ILD) combined with AC are extremely rare. Clinicians have limited awareness of this comorbidity, and AC nodules occurring against a background of ILD are easily confused with fibrotic or inflammatory lesions, leading to a high rate of clinical misdiagnosis and missed diagnosis. Herein, we report a case from our institution: the patient was found to have bilateral pulmonary interstitial changes and nodules on routine chest CT, and was initially diagnosed with connective tissue disease-associated interstitial lung disease (CTD-ILD) based on pathological and ancillary examinations. Several years later, the patient presented with dizziness related to brain metastases and was finally diagnosed with AC. By analyzing the entire diagnosis and treatment process of this case, we aim to improve clinicians' ability to recognize such rare cases and provide clinical guidance for their early diagnosis and appropriate treatment.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"574-578"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20250826-00518
{"title":"[Guidelines for the diagnosis and treatment of tracheobronchial tuberculosis (2025 Edition)].","authors":"","doi":"10.3760/cma.j.cn112147-20250826-00518","DOIUrl":"10.3760/cma.j.cn112147-20250826-00518","url":null,"abstract":"<p><p>Tracheobronchial tuberculosis (TBTB) is a special clinical type of pulmonary tuberculosis (MTB), belonging to lower respiratory tract tuberculosis. Due to its non-specific clinical manifestations, it is prone to misdiagnosis, underdiagnosis, mistreatment, and missed treatment in clinical practice. To enhance the early and accurate diagnosis and timely and standardized treatment of TBTB in clinical practice, the Tuberculosis Branch of the Chinese Medical Association organized experts in relevant fields, adopted evidence-based medical methods, basing on the original consensus and guidelines (trial), and mainly made the following updates: New evidence quality evaluation, recommendation strength, consensus rate, and molecular biological detection methods were added; the original term \"bacteriology\" was revised to \"etiology\"; the diagnostic methods and criteria were supplemented and improved, with emphasis on revising the original clinical classification and staging diagnosis to bronchoscopic classification and staging diagnosis; the treatment methods for TBTB were comprehensively and systematically introduced; the interventional treatment principles for different classifications and stages were recommended, especially emphasizing the emergency treatment methods for extremely severe and severe tracheal tuberculosis combined with tracheal stenosis in order to improve the diagnosis and treatment.This guideline specifically presents 31 recommendations around the following 22 common clinical issues, with the aim of improving the diagnosis and treatment level of TBTB in clinical practice and benefiting more patients.<b>The recommendations are listed below:</b><b>Recommendation 1:</b> Definition of TBTB: Tuberculosis that occurs in the mucosa, submucosa and outer membrane of the tracheas and bronchi.<b>Recommendation 2:</b> Typical clinical manifestations of TBTB: Irritating cough, expectoration, hemoptysis, wheezing and varying degrees of breathing difficulties lasting more than 2 weeks, and wheezing sounds in the lungs, dry and wet rales, weakened or absent breathing sounds, tracheal deviation, etc.<b>Recommendation 3:</b> Typical imaging signs that should be paid special attention to: during clinical review of chest CT scans, not only the lung window, mediastinal window and soft tissue signs should be emphasized, but also the signs within the airway, on the airway wall and outside the airway should be closely observed. When TBTB is suspected, it is recommended to perform multi-dimensional airway reconstruction imaging technology with chest CT.<b>Recommendation 4:</b> Etiological testing of TBTB: Biopsy tissues, brush specimens, lavage fluids, lavage fluids and puncture materials can be obtained with bronchoscopy. Relevant acid-resistant staining, culture & drug sensitivity tests and molecular etiology of Mycobacterium tuberculosis should be conducted.<b>Recommendation 5:</b> Pathological features of TBTB: It is consistent with tuberculosis changes ","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"503-524"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20251120-00279
R Y Zhang, X F Liu, Q L Chen, X J Yao, Y H Wang, R Li, X M Wang, Y Y He, X C Zhang
{"title":"[Blood eosinophil count and clinical characteristics in patients with bronchiectasis].","authors":"R Y Zhang, X F Liu, Q L Chen, X J Yao, Y H Wang, R Li, X M Wang, Y Y He, X C Zhang","doi":"10.3760/cma.j.cn112147-20251120-00279","DOIUrl":"10.3760/cma.j.cn112147-20251120-00279","url":null,"abstract":"<p><p><b>Objective:</b> To explore the clinical characteristics of bronchiectasis patients with different levels of peripheral blood eosinophils. <b>Methods:</b> This study was a retrospective study. A total of 162 stable non-cystic fibrosis bronchiectasis patients were enrolled from Capital Medical University, Beijing Tongren Hospital from June 2022 to May 2025. Among them, there were 79 males and 83 females, aging 20-85 (60.27±15.83) years. Blood eosinophil(EOS) count (cells/μl, 100 cells/μl=0.1×10<sup>9</sup>/L) was used as the cut-off value to classify patients into high BEC (blood eosinophil count) group, (Blood EOS≥300 cells/μl), medium BEC group (100 cells/μl≤Blood EOS<300 cells/μl) and low BEC group (blood EOS<100 cells/μl). The differences in general information, clinical symptoms, laboratory tests, pulmonary function and imaging characteristics, modified British Medical Research Council dyspnea scale (mMRC) score, bronchiectasis severity index (BSI), FACED scores, bronchiectasis imaging Reiff score and acute exacerbation events in the past year were compared among the three groups. The risk factors for acute exacerbation hospitalization of bronchiectasis in the three groups were analyzed. Data analysis was performed using SPSS 25.0 and R 4.2.2 software. <b>Results:</b> The proportions of patients with high, medium, and low BEC were 22.22%, 48.77% and 29.01%, respectively. Among the three groups, the comorbidity of rhinitis, sinusitis, nasal polyps, atopic dermatitis, respiratory symptoms, mMRC and CAAT scores, BAS%, BAS count, serum IgE, induced sputum EOS%, FeNO, IL-4, IL-5, positive proportion of allergens, positive proportion of Pseudomonas aeruginosa(PA) in sputum culture, positive proportion of fungi, FEV<sub>1</sub> improvement rate, BSI, Reiff score, the proportion of cylindrical bronchiectasis, the occurrence of acute exacerbations[86.11% (31/36) <i>vs.</i> 49.37% (39/79) <i>vs.</i> 72.34% (34/47), <i>χ</i><sup>2</sup><i>=</i>16.44,<i>P</i><0.001] and hospitalizations[38.89%(14/36) <i>vs.</i> 22.78%(18/79) <i>vs.</i> 48.94%(23/47),<i>χ</i><sup>2</sup>=9.49,<i>P</i>=0.009] were statistically significant among the three groups (<i>P</i><0.05). The high BEC group had more severe clinical symptoms, a higher prevalence of nasal polyps, higher levels of type 2 inflammatory biomarkers, and a higher frequency of acute exacerbation, but lower rates of hospitalization for acute exacerbation hospitalization, lower BSI score, and less pulmonary imaging involvement. IgE(<i>OR</i>=1.002,95%<i>CI</i>:1.000-1.003,<i>P</i>=0.029) was a risk factor for acute exacerbation hospitalization in high BEC group. MMRC(<i>OR</i>=2.879,95%<i>CI</i>:1.345-6.162,<i>P</i>=0.006) and PA infection(<i>OR</i>=4.427,95%<i>CI</i>:1.129-17.358,<i>P</i>=0.033) were independent risk factors for acute exacerbation hospitalization in the medium BEC group. PA infection(<i>OR</i>=8.649,95%<i>CI</i>:1.932-38.724,<i>P</i>=0.005) was an independent risk factor for acute exac","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"546-554"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20250915-00566
{"title":"[Clinical practice guidelines for the management of influenza in adults with chronic airway diseases].","authors":"","doi":"10.3760/cma.j.cn112147-20250915-00566","DOIUrl":"10.3760/cma.j.cn112147-20250915-00566","url":null,"abstract":"<p><p>Respiratory infections are the most important trigger of acute exacerbations of chronic airway diseases. As a prevalent pathogen, the influenza virus accounts for a markedly higher proportion of cases during epidemic seasons. Patients with chronic airway diseases constitute a high-risk population for influenza; upon infection, their clinical manifestations, diagnosis, treatment and prevention all exhibit distinct characteristics underscoring the urgent need for standardized clinical management. In light of the expanding body of evidence-based research in this field, this guideline addresses 12 critical clinical questions, ranging from influenza prevention and screening to antiviral management, comorbidity care, and the integration of traditional Chinese medicine. By offering 11 targeted recommendations, this document clarifies essential protocols-including annual vaccination indications, pre- and post-exposure prophylaxis, early etiological detection, and the rational application of antibacterials and glucocorticoids-to provide guidance for both general practitioners and respiratory specialists.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"525-538"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20250901-00532
H W Wang
{"title":"[Prioritizing interventional diagnosis and treatment for tracheobronchial tuberculosis: paradigm shift and clinical practice enhancement based on the 2025 guidelines].","authors":"H W Wang","doi":"10.3760/cma.j.cn112147-20250901-00532","DOIUrl":"10.3760/cma.j.cn112147-20250901-00532","url":null,"abstract":"<p><p>Tracheobronchial tuberculosis (TBTB) is a key cause of long-term lung function impairment and diminished quality of life in pulmonary tuberculosis patients. Although the <i>Guidelines for the diagnosis and treatment of tracheobronchial tuberculosis (2025 Edition)</i> systematically establishes a new diagnosis and treatment framework, prevalent issues in clinical practice-including insufficient awareness, delayed diagnosis, and non-standardized technical application-severely constrain the improvement of TBTB treatment outcomes. This article aims to integrate the core updates of the new guidelines with the latest international research advances to analyze the severe challenges currently faced in TBTB diagnosis and treatment. It advocates for the foundational role of bronchoscopic interventional technology in the comprehensive management of the disease and calls on clinicians to restructure clinical practice with the philosophy of \"early intervention, precise classification, and multidisciplinary collaboration\" to meaningfully improve the prevention and management of TBTB.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"496-499"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华结核和呼吸杂志Pub Date : 2026-05-12DOI: 10.3760/cma.j.cn112147-20251031-00669
B Xue, Y G Wang, W J Wu, T Wang, X Chen, H Zhao, R R Zhou, H X Yin, X P Shi, Y P Li, X Sha, J Zhang
{"title":"[Treatment of benign acquired esophagorespiratory fistula with through-the-clip device: a report of 2 cases and literature review].","authors":"B Xue, Y G Wang, W J Wu, T Wang, X Chen, H Zhao, R R Zhou, H X Yin, X P Shi, Y P Li, X Sha, J Zhang","doi":"10.3760/cma.j.cn112147-20251031-00669","DOIUrl":"10.3760/cma.j.cn112147-20251031-00669","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the feasibility and clinical efficacy of through-the-scope clips(TTS Clips) closure technique for benign acquired esophagorespiratory fistulas. <b>Methods:</b> The clinical data of 2 patients with benign acquired esophagorespiratory fistulas successfully treated at the Chuiyangliu Hospital Affiliated with Tsinghua University were retrospectively analyzed. The size and location of the fistula were assessed from the esophageal side. Argon plasma coagulation (APC) was used first to coagulate and trim the mucosa around the fistula margins to create a fresh wound surface, and also, to symmetrically relieve tension around the orifice for the bigger fistula. Finally, TTS Clips were applied to close the fistula under gastroscopy. Relevant literature was retrieved from PubMed, Wanfang, and CNKI databases to systematically analyze the current status and factors influencing healing of endoscopic clipping for benign acquired esophagorespiratory fistula. <b>Results:</b> Both patients successfully underwent endoscopic closure with TTS Clips after thorough preoperative evaluation. One patient with a fistula <5 mm achieved clinical healing after one clipping procedure. while the patient with a 14 mm×8 mm fistula achieved clinical healing after three endoscopic clipping sessions over a 4-month period. Literature review revealed that endoscopic clipping has been extensively reported for gastrointestinal fistulas, while data on its application for benign tracheoesophageal fistulas remain scarce. Nevertheless, existing evidence supports the methodological feasibility of this approach for benign esophagorespiratory fistulas. <b>Conclusion:</b> Endoscopic TTS clips closure for benign esophagorespiratory fistulas is a minimally invasive, repeatable and safe approach that can achieve clinical healing, representing an effective treatment option for this condition.</p>","PeriodicalId":61512,"journal":{"name":"中华结核和呼吸杂志","volume":"49 5","pages":"567-573"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}